PXT002331 A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2016
At a glance
- Drugs Foliglurax (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; First in man
- Sponsors Prexton Therapeutics
- 27 Sep 2016 Status changed from recruiting to completed.
- 28 Jan 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
- 30 Dec 2015 New trial record